# A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

> **NCT04365036** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 207 (estimated)

## Conditions studied

- NK/T Cell Lymphoma Nos

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Pegaspargase
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **RADIATION:** Definitive intensity-modulated radiotherapy (IMRT)

## Key facts

- **NCT ID:** NCT04365036
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-03
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04365036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04365036, "A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04365036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*